Diffuse intrinsic pontine gliomas (DIPGs) are highly infiltrative malignant glial neoplasms of the ventral pons that, due to their location within the brain, are unsuitable for surgical resection and consequently have a universally dismal clinical outcome. The median survival time is 9-12 months, with neither chemotherapeutic nor targeted agents showing substantial survival benefit in clinical trials in children with these tumors 1 . We report the identification of recurrent activating mutations in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, in 21% of DIPG samples. Strikingly, these somatic mutations (encoding p.Arg206His, p.Arg258Gly, p.Gly328Glu, p.Gly328Val, p.Gly328Trp and p.Gly356Asp substitutions) have not been reported previously in cancer but are identical to mutations found in the germ line of individuals with the congenital childhood developmental disorder fibrodysplasia ossificans progressiva (FOP) 2 and have been shown to constitutively activate the BMP-TGF-b signaling pathway. These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.
Recent high-throughput sequencing approaches have found a striking prevalence of mutations in the genes for the histone variants H3.3 (H3F3A) or H3.1 (HIST1H3B) that encode p.Lys27Met substitutions in the childhood brain tumor DIPG 3 . This lysine-to-methionine substitution confers a trans-dominant ablation of global trimethylation at lysine 27 of histone H3 (H3K27me3), which likely profoundly alters gene expression through the derepression of Polycomb repressive complex 2 (PRC2) target genes 4 . Despite these advances in understanding of the distinct biology of these tumors 1 , approaches for desperately needed specific therapeutic interventions are not clear, and little has been reported of the additional mutations accompanying these changes.
We carried out whole-genome sequencing on a unique series of 20 pretreatment biopsy samples of DIPG, for which the patients underwent a safe stereotactic procedure 5 , and whole-exome sequencing on a further biopsy case as well as 5 samples obtained at autopsy ( Supplementary Table 1 ). Histone H3 gene mutations encoding p.Lys27Met were observed in 23 of 26 cases (88%), comprising 15 (58%) H3F3A mutations and 8 (31%) HIST1H3B mutations ( Fig. 1a) . These were not found in concert with mutations in the chaperones ATRX or DAXX as has been described for supratentorial pediatric glioblastoma (pGBM) 6 . There was also an absence of other known glioma-related molecular abnormalities such as IDH1, IDH2, BRAF or FGFR1 mutations and gene fusions. The mutational spectrum of the untreated biopsy cases was not significantly different from that of the autopsy cases (P > 0.05; Fig. 1b ), although the treatment-naive samples had a low overall mutation rate, with a mean of 14.8 somatic single-nucleotide variants (SNVs) per sample (range of 0-25), that was significantly lower than observed in the radiation-treated autopsy cases (mean = 32.0, range = 14-50; P = 0.004, t test). Similarly, there was a significantly lower overall mutation rate in untreated samples taken at biopsy than in autopsy samples (mean of 0.76 versus 1.2 mutations per megabase; P = 0.023, t test).
Eleven of 26 DIPGs (42%) harbored somatic TP53 mutations, with a further 6 cases (23%) shown to have SNVs in PPM1D, which encodes a regulator of p38 mitogen-activated protein kinase (p38-MAPK)-p53 signaling in response to cellular stress, and an additional case with a somatic ATM mutation ( Supplementary Fig. 1 ), demonstrating nonoverlapping targeting of a DNA damage response pathway in 18 of 26 DIPGs (69%) ( Supplementary Fig. 2 ). We further identified nonoverlapping recurrent alterations in the phosphoinositide 3-kinase (PI3K) pathway targeting PIK3CA, PIK3R1 and PTEN through SNVs and microdeletion ( Supplementary Fig. 3 ), in addition to amplification of MET (1/26; 4%) as previously described 7, 8 and truncating Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma l e t t e r s mutation of NF1 (1/26; 4%) ( Fig. 1c) . We also identified new recurrent somatic mutations in IGF2R (2/26; 8%), although these mutations were concurrent with others in the pathway, such that their consequences are unknown. In total, 12 of 26 DIPG cases (46%) harbored some form of alteration predicted to activate the receptor tyrosine kinase (RTK)-PI3K-MAPK pathways (Supplementary Fig. 4 ).
Heterozygous somatic coding mutations in the ACVR1 gene, which encodes the activin A type I receptor ALK2, were observed in 7 of 26 cases (27%) (Fig. 1c) . These were restricted specifically to codons 328 (c.983G>T, p.Gly328Val, two cases; c.983G>A, p.Gly328Glu, two cases), 258 (c.772C>T, p.Arg258Gly, one case) and 356 (c.1067G>A, p.Gly356Asp, one case), all within the serine/threonine kinase domain, and 206 (c.617G>A, p.Arg206His, one case), within the glycine-serine-rich (GS) domain. Screening an extended series of 26 DIPG biopsy samples by Sanger sequencing identified further recurrences of these mutations and an additional variant at NCHP_DIPG061  NCHP_DIPG102  HSJD_DIPG001  NCHP_DIPG112  NCHP_DIPG111  NCHP_DIPG109  NCHP_DIPG065  NCHP_DIPG006  HSJD_DIPG003  HSJD_DIPG008  NCHP_DIPG107  NCHP_DIPG101  HSJD_DIPG007  HSJD_DIPG002  NCHP_DIPG011  NCHP_DIPG108  HSJD_DIPG004  NCHP_DIPG052  NCHP_DIPG113  NCHP_DIPG114  NCHP_DIPG106  NCHP_DIPG104  NCHP_DIPG110 npg l e t t e r s position 328 (c.982G>T, p.Gly328Trp) (Supplementary Fig. 5 ).
Overall, we identified 11 of 52 DIPG samples (21%) harboring mutation in ACVR1 at 4 different codons ( Fig. 2a) . These mutations appear highly specific to DIPG. SNVs in the ACVR1 coding region are present in the Catalogue of Somatic Mutations in Cancer (COSMIC) database 9 at an overall frequency of 20 in 5,965 (0.3%), with no individual tumor type harboring them with a frequency of greater than 2% and no mutations observed to affect any of the 2 0 2 1 22 2 0 2 1 22 npg l e t t e r s residues described in the present study, suggestive of a 'passenger' effect in other cancers. ACVR1 mutations were found to cosegregate with the less common HIST1H3B mutation encoding p.Lys27Met in the canonical histone H3.1 variant (P < 0.0001, Fisher's exact test) (Fig. 2b) , as well as with wild-type TP53 (P = 0.0103, Fisher's exact test). There was also an association between H3.1 alteration and chromosome 2 gain (on which ACVR1 is found at 2q24.1; P = 0.0009, Fisher's exact test). ACVR1 mutations seem to mark a distinct subset of DIPG cases (Supplementary Table 2) . There was a marked predominance of females in the ACVR1-mutant tumor group compared to cases with wild-type ACVR1 (1.75:1 versus 0.64:1 female to male ratios, respectively; P = 0.05, Fisher's exact test) (Fig. 2c) , as well as a relatively restricted age of onset (Fig. 2d) . Cases with tumors harboring ACVR1 mutations also had longer overall survival times (median of 14.9 versus 10.9 months; P = 0.05, log-rank test) ( Fig. 2d) , although outcome remained very poor. There were no significant differences in histology between the groups (Fig. 2e) . Whole-genome sequencing of biopsy samples exemplifying the genotype with concurrent ACVR1 and HIST1H3B mutations harbored an additional 10-19 somatic SNVs and 0-9 structural variations ( Fig. 2f) .
Remarkably, these somatic mutations in ACVR1 affected identical residues as the ones described in the germ line of individuals with the autosomal dominant congenital childhood developmental disorder FOP (MIM 135100) 2 . This debilitating disease is characterized by heterotopic ossification of soft connective tissue resulting in severe skeletal abnormalities 10 . Individuals with classical clinical features of FOP carry heterozygous mutations in ACVR1 encoding p.Arg206His that affect the GS activation domain 11 , whereas atypical cases with a less severe phenotype have been shown to harbor either mutations encoding p.Arg258Ser 12 , p.Gly328Glu, p.Gly328Arg or p.Gly328Trp 13 or p.Gly356Asp 14 or other heterozygous mutations affecting the GS and kinase domains 2, 15 . This latter series of alterations may be exposed to be present at the interface with the GS domain and may abrogate interactions with the negative regulator FKBP12 (refs. 12,13,15 ). These mutations have been shown to constitutively activate the bone morphogenetic protein (BMP)-dependent transforming growth factor (TGF)-β pathway in the absence of ligand binding, as evidenced by increased phosphorylation of SMAD1, SMAD5 and SMAD8 (SMAD1/5/8) in vitro 14, 16 .
To investigate the specific role of ACVR1 mutations in the context of DIPG, we assembled a panel of four DIPG case-derived primary cultures (and one thalamic pediatric GBM (glioblastoma multiforme) culture harboring an H3F3A mutation encoding p.Lys27Met), representing two ACVR1 mutations (encoding p.Arg206His and p.Gly328Val) and three wild-type lines ( Supplementary Table 3 ). In these models, RNA sequencing (RNA-seq) data demonstrated that the mutant allele was expressed in approximately half of the reads, which was also evidenced by Sanger sequencing of cDNA from case sample NCHP_DIPG011 (Supplementary Fig. 6) . Treatment with the selective ALK2 inhibitor LDN-193189 (ref. 17) resulted in marked inhibition of cell viability in all cells, with GI 50 values (concentrations required to inhibit cell growth by 50%) ranging from 0.86-2.1 µM, approximately tenfold lower than with the less potent parent compound dorsomorphin, with a trend toward increased sensitivity in the mutant cultures (P = 0.10, F test) (Fig. 3a) . Transfection of thalamic GBM and DIPG cells with wild-type ACVR1 (both with H3F3A mutation encoding p.Lys27Met) with constructs encoding Flag-tagged mutants conferred increased signaling through phosphorylated SMAD1/5/8, particularly for the Arg206His mutant and, to a lesser extent, for the Gly328Glu mutant (Fig. 3b) . ACVR1 mutation may only be one mechanism by which this pathway is activated in DIPG, however, as high basal levels of phosphorylated SMAD1/5/8 were also observed for the cells with H3F3A mutation encoding p.Lys27Met and wild-type ACVR1 that were used in this study ( Supplementary  Fig. 7) . This finding may explain the lack of a more robust genotypedependent response to the inhibitor and may also expand the population of patients who might benefit from targeting of the receptor.
There are no reports to our knowledge of coincident FOP and DIPG, although the clinical features of both typical and atypical cases of FOP can commonly include neurological symptoms and have been reported in children to include cerebellar and brain stem abnormalities 15, 18 , including demyelinated lesions in the pons, both in human cases and mouse models 19 . It will nonetheless be a challenge to identify the mechanism by which the temporal and spatial context of BMP-TGF-β pathway activation confers such differing clinical phenotypes. In experimental models of FOP, ACVR1 mutations are associated with defects in stem cell maintenance, reprogramming and differentiation, offering links with cancer-related cellular processes. First-generation ALK2 inhibitors such as dorsomorphin 20 and LDN-193189 (ref. 17) have been shown to downregulate intracellular BMP-TGF-β signaling and to reduce heterotypic ossification, opening the tantalizing possibility of central nervous system (CNS)penetrant compounds showing a similar potential in a childhood brain tumor otherwise devoid of efficacious treatment options. 
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